Japan approved T-DXd plus pertuzumab for HER2-positive disease and Dato-DXd for triple-negative disease in first-line metastatic breast cancer.
Feature|Articles|June 26, 2025
Ongoing Trials Aim to Remove Carboplatin from TCHP and Reduce Treatment Cycles in HER2+ Breast Cancer
Author(s)Ashley Chan
Fact checked by: Kyle Doherty
As the HER2-positive breast cancer landscape continues to evolve, the omission of carboplatin in TCHP could drive significant change.
Advertisement
Advertisement
Within the past decade, the HER2-positive breast cancer landscape has demonstrated significant improvements. However, coming off the heels of the
Related to this article
A marketing authorization application for lirafugratinib in previously treated FGFR2-altered metastatic cholangiocarcinoma has been submitted to the EMA.
Toon Van Gorp, MD, PhD, discusses NAPISTAR 1-01 trial design, safety findings, and efficacy across dose levels of TUB-040 in ovarian cancer.
A PET-guided, nivolumab-based regimen produced promising response rates in advanced-stage classical Hodgkin lymphoma.
The University of Texas MD Anderson Cancer Center and Springer Nature will co-host a conference to explore the latest research on cancer therapeutics.
Cesalatamig earned FDA fast track designation for NSCLC that progressed after immunotherapy and platinum-based chemotherapy.
Data from a retrospective study showed high levels of CEACAM1 expression in patients with mantle cell lymphoma.
The phase 2 AMIGO-1 trial met its end point, with an 18-month PFS rate of 66.7% for first-line amivantamab, lazertinib, and pemetrexed in EGFR-mutant NSCLC.
Advertisement
Advertisement